EDG-5506
Becker Muscular Dystrophy (BMD)
Key Facts
About Edgewise Therapeutics
Edgewise Therapeutics is on a mission to develop transformative oral therapies for rare muscle disorders by targeting the fundamental biology of muscle contraction. Its core achievement is the rapid clinical advancement of EDG-5506, a selective myosin modulator now in Phase 2/3 trials for Becker muscular dystrophy and Phase 2 for Duchenne muscular dystrophy. The company's strategy leverages a proprietary platform to address a critical pathophysiological driver—excessive muscle contraction—across multiple myopathies. This focused approach has established Edgewise as a leader in the neuromuscular space, backed by strong investor confidence and a clear regulatory pathway.
View full company profileAbout Edgewise Therapeutics
Edgewise Therapeutics is on a mission to develop transformative oral therapies for rare muscle disorders by targeting the fundamental biology of muscle contraction. Its core achievement is the rapid clinical advancement of EDG-5506, a selective myosin modulator now in Phase 2/3 trials for Becker muscular dystrophy and Phase 2 for Duchenne muscular dystrophy. The company's strategy leverages a proprietary platform to address a critical pathophysiological driver—excessive muscle contraction—across multiple myopathies. This focused approach has established Edgewise as a leader in the neuromuscular space, backed by strong investor confidence and a clear regulatory pathway.
View full company profileAbout Edgewise Therapeutics
Edgewise Therapeutics is on a mission to develop transformative oral therapies for rare muscle disorders by targeting the fundamental biology of muscle contraction. Its core achievement is the rapid clinical advancement of EDG-5506, a selective myosin modulator now in Phase 2/3 trials for Becker muscular dystrophy and Phase 2 for Duchenne muscular dystrophy. The company's strategy leverages a proprietary platform to address a critical pathophysiological driver—excessive muscle contraction—across multiple myopathies. This focused approach has established Edgewise as a leader in the neuromuscular space, backed by strong investor confidence and a clear regulatory pathway.
View full company profileTherapeutic Areas
Other Becker Muscular Dystrophy (BMD) Drugs
| Drug | Company | Phase |
|---|---|---|
| Myomatrix Stabilization Program | Strykagen | Preclinical |
| Vamorolone | ReveraGen BioPharma | Clinical Testing |